Emergent BioSolutions (EBS) Competitors

Geron (NASDAQ:GERN) and Emergent BioSolutions (NYSE:EBS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

Do analysts prefer GERN or EBS?

Geron presently has a consensus target price of $5.75, indicating a potential upside of 363.71%. Emergent BioSolutions has a consensus target price of $14.33, indicating a potential upside of 211.59%. Given Geron's higher possible upside, analysts plainly believe Geron is more favorable than Emergent BioSolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.82
Emergent BioSolutions	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has higher valuation and earnings, GERN or EBS?

Geron has higher earnings, but lower revenue than Emergent BioSolutions. Geron is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$76.99M	10.26	-$184.13M	-$0.27	-4.59
Emergent BioSolutions	$1.01B	0.25	-$760.50M	-$3.73	-1.23

Does the MarketBeat Community favor GERN or EBS?

Geron received 71 more outperform votes than Emergent BioSolutions when rated by MarketBeat users. Likewise, 70.03% of users gave Geron an outperform vote while only 66.82% of users gave Emergent BioSolutions an outperform vote.

Company	Underperform	Outperform
Geron	Outperform Votes 500 70.03%	Underperform Votes 214 29.97%
Emergent BioSolutions	Outperform Votes 429 66.82%	Underperform Votes 213 33.18%

Which has more risk & volatility, GERN or EBS?

Geron has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500.

Do institutionals and insiders believe in GERN or EBS?

73.7% of Geron shares are held by institutional investors. Comparatively, 78.4% of Emergent BioSolutions shares are held by institutional investors. 3.1% of Geron shares are held by insiders. Comparatively, 3.2% of Emergent BioSolutions shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Does the media prefer GERN or EBS?

In the previous week, Geron had 35 more articles in the media than Emergent BioSolutions. MarketBeat recorded 36 mentions for Geron and 1 mentions for Emergent BioSolutions. Emergent BioSolutions' average media sentiment score of 1.73 beat Geron's score of 0.05 indicating that Emergent BioSolutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	3 Very Positive mention(s)	3 Positive mention(s)	22 Neutral mention(s)	5 Negative mention(s)	2 Very Negative mention(s)	Neutral
Emergent BioSolutions	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Is GERN or EBS more profitable?

Emergent BioSolutions has a net margin of -18.55% compared to Geron's net margin of -682.48%. Emergent BioSolutions' return on equity of -9.91% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-682.48%	-67.53%	-45.46%
Emergent BioSolutions	-18.55%	-9.91%	-3.31%

Summary

Emergent BioSolutions beats Geron on 10 of the 19 factors compared between the two stocks.